Therapeutic Potential of Refanalin in Pulmonary Fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL076959-01A1
Agency Tracking Number: HL076959
Amount: $175,272.00
Phase: Phase I
Program: SBIR
Awards Year: 2004
Solicitation Year: 2004
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2
Small Business Information
ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP, 350 COMMUNITY DR, RM 129, MANHASSET, NY, 11030
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 LATHA Paka
 (516) 562-1278
 SPAKA@ANGION.COM
Business Contact
 ITZHAK GOLDBERG
Phone: (516) 869-6400
Email: GOLDBERG@ANGION.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a devastating disease with less than a 50% five-year survival. While steroids and other immunosuppressive agents serve as the standard treatment for IPF, these agents have pro

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government